|
Annals of African Medicine
Annals of African Medicine Society
ISSN: 1596-3519
Vol. 3, Num. 3, 2004, pp. 116-119
|
Annals of African Medicine, Vol. 3, No. 3, 2004, pp. 116-119
ANTI-TUBERCULOUS CHEMOTHERAPY: 120 YEARS ON
C. N. Ekweani
Department of Medicine, Ahmadu Bello University Teaching Hospital, Kaduna, Nigeria
Reprint requests to: Dr. C. N. Ekweani, Department of Medicine, A. B.
U. Teaching Hospital, Kaduna, Nigeria
Code Number: am04029
ABSTRACT
The last 120 years have witnessed the discovery
of very effective drugs for the treatment of tuberculosis and the evolution
of anti-tuberculous drug regimens to the present state where the disease
can be cured with the use of 4 or more drugs given for 6 - 12 months provided
the drugs are taken regularly and for long enough. The DOTS strategy makes
this possible. With this development the outlook for the TB patient has markedly
improved and the prospect for the worldwide control of this rampant and dreadful
disease is bright. However certain obstacles have to be overcome before this
prospect can be fully realised. These include poverty and poor living conditions,
the scourge of HIV/AIDS and the inefficient use of anti-tuberculous drugs.
Key words: Tuberculosis, chemotherapy, poverty,
HIV/AIDS
INTRODUCTION
It is about 120 years since
Robert Koch discovered the tubercle, bacillus, the organism that causes tuberculosis
(TB). That important discovery raised the possibility of a cure for this
dreadful disease and aroused an intense interest in chemotherapy. This led
to many animal studies and clinical trials. 1 As a result of these
studies and trials, the first effective anti-tuberculous drug, streptomycin,
was discovered in 1944 by Schatz, Bugie and Waksman. 2 Thereafter,
other effective drugs were discovered and chemotherapy has now become the
mainstay of management of tuberculosis. Yet the goal of relieving all suffering
from tuberculosis in the world, let alone eradicating it, remains as elusive
as it must have been in 1882. The disease is still rampant in developing
countries due to poor living conditions, overcrowding and inefficient use
of effective chemotherapy. Another major factor contributing to the high
prevalence in these countries is the human immunodeficiency virus (HIV),
which impairs the immune defenses of affected persons, predisposing them
to opportunistic infections such as tuberculosis.
Non-pharmacological measures
The development of modern
effective anti-tuberculosis chemotherapy was preceded by numerous non-pharmacological
measures such as hygienic measures, sanatorium treatment, the practice of
artificial pneumothorax, thoracoplasty and immunotherapy by the injection
of tuberculin.
The efficacy of these measures
was however difficult to prove in the absence of controlled trials. Gold
therapy followed from 1925 to 1935 but, like previous attempts, its efficacy
could not be proven.
Sulphonamides, Streptomycin,
PAS, INH
The first effective anti-tuberculous
chemotherapeutic agents were the sulphonamides, followed by streptomycin,
para-aminosalicylic (PAS) acid and isoniazid (INH). Their efficacy was demonstrated
by numerous clinical trials. 3 - 20
These trials highlighted the efficacy of streptomycin
and the sulphonamides in the treatment of tuberculosis, the problem of bacterial
resistance when these agents were used alone, and the value of combining
streptomycin and/or PAS with INH as a solution to the problem of resistance.
Another trial 21 showed that the optimal duration of therapy with
these drugs was 2 years.
The Madras study 22 proved that ambulatory
treatment was as effective as in-patient treatment while another Madras study 23 showed
that intermittent treatment was first as effective as continuous treatment
and had the advantage of improving patient compliance and reducing cost.
Short course therapy
The next major development
was short course therapy. The introduction of rifampicin and pyrazinamide
in the early 1970s made possible regimens of 9 months as in
the so-called short-course therapy. This form of therapy is based on the
observations both in vivo and in vitro from several studies showing that
rifampicin and pyrazinamide eliminate special bacterial populations. Rifampicin
acts mainly against rapidly dividing bacilli. Pyrazinamide on the other hand,
acts against the so-called persisters organisms that are metabolizing or
dividing very slowly. 24 - 30
Short-course regimes consist of an initial intensive
phase that includes combinations of bacterial drugs namely rifampicin, pyrazinamide,
INH and streptomycin followed by a continuation phase of either twice-weekly
or daily drugs. A review by Fox 31 of selected short course regimens
has shown that bacteriostatic drugs play little or no role in such regimens.
The implications and benefits of short course
therapy include;
- Total quality
of drugs used is less, which means less chronic toxicity and less cost.
- Total delivery
of health services is less
- More efforts
can be concentrated on ensuring patient compliance.
- Patients who
abscond early are less likely to relapse.
- Routine follow-up
after the end of treatment can be abandoned.
Short-course therapy is currently
the most effective treatment for most patients with tuberculosis and has
been recommended by World Health Organisation (WHO) as part of the directly
observed treatment short course (DOTS) strategy for the world-wide control
of tuberculosis. With this strategy, WHO envisages that in those countries
where the incidence of tuberculosis is stable and HIV I absent, given a 70%
case detection rate and 85% cure rate, the annual incidence of the disease
will reduce by 11% per year. 32
Current recommendations for the treatment of
pulmonary and extra-pulmonary tuberculosis are given below. 33 With
regards to the notations used for anti-tuberculous treatment regimens outlined
hereunder, the drugs are represented by the letters of the alphabets e.g.
R (Rifampicin); H (INH); Z (Pyrazinamide); E (Ethambutol); S (streptomycin)
while the durations of therapy in months is represented by Arabic numerals
e.g. 2, 4, 6.
Section 1: Pulmonary tuberculosis
Category A: Uncomplicated tuberculosis
Category A1: Primary treatment (no treatment
within the previous 5 years): 2HRZ + (E or S). 4HR.
The drugs may be given daily or intermittently
(thrice weekly) in both the initial and continuation phases. For patients
with extensive disease or evidence of drug resistant TB the initial phase
may be extended to 3 or 4 months while the total duration of treatment may
remain at 6 months.
Category A2: Re-treatment: (for those
who have received treatment within the previous 5 years): 3(4) HRZES. 6(5)
HR + or E.
Category B: Drug resistant tuberculosis
There are no documented regimes
for these types of tuberculosis. It is important to avoid the addition phenomenon-namely
adding a single drug to a failing regimes. Otherwise acquired resistance
to the newly added drug will develop. Instead add at least 2, 3 or more drugs
to which the organisms ARE sensitive or which had not already been administered
to the patient. Treatment duration should not be less than 12 months in this
case.
Category C: Multi-drug-resistant
TB (MDR-TB)
For MDR-TB, that is TB that
is resistant to at least isoniazid and rifampicin. A combination of drugs
to which the organism is likely to be sensitive should be used, namely, a
regimes that includes 5 or 6 drugs for the initial 6 months and then 3 or
4 drugs subsequently. Apart from the first-line drugs other drugs available
include the quinolones (e.g. ofloxacin, levofloxacin, ciprofloxacin), prothionamide,
ethionamide, cycloserine, para-amino salicylic acid, clofazimine and the
aminoglycosides kanamycin, amikacin. The optimal duration of treatment for
MDR-TB has not been clearly established but some authorities recommend a
total duration of 18 to 24 months or 24 months after negative culture. With
the inclusion of quinolones duration may be shortened to 12 to 18 months.
The longer duration may be required for patients with diabetes mellitus,
silicosis, slow sputum conversion or extensive disease.
Section 2: Extrapulmonary
tuberculosis
Due to lack of a sufficient
number of larger-scale studies consensus is lacking especially on the optima
duration of treatment. The following regimes are recommended based on limited
current evidence and local experience. Adjunctive steroid treatment can be
useful in tuberculous pericarditis, tuberculous meningitis, tuberculous lymphadenitis,
tuberculous pleural effusion, fulminant pulmonary tuberculosis and genitourinary
tuberculosis.
Category A: TB Meningitis
including central nervous system TB
3HRZE. 9HRZ.
Streptomycin may be added
for the initial 2 months and duration may be extended to 18 or 24 months
for CNS tuberculosis.
Category B: Miliary TB
3HRZ + (E or S). 9HR
Category C: TB of bone and joint
2HRZE/1OHR.
Duration if treatment
may be reduced to 6 or 9 months in the case of TB spine or other cases
of mild disease.
Category D: TB lvmphadenitis
Where lymph node affection
in the neck is solitary or few, limited to the upper cervical chain or posterior
triangle and the chest X-ray is clear, the same treatment as outlined in
section 1 category A is recommended and should be given for 6 months.
For other situations the duration
of therapy should be 9 months. It has to be noted that the clinical response
of TB of the lymph nodes during treatment may be quite unpredictable sometimes
with paradoxical increases in size probably due to immunological reactions.
Furthermore residual nodes may still be palpable after completing the full
course of treatment.
Category E: TB pericarditis, TB
peritonitis and genitourinary TB
The recommendation is as in
section 1 Category Al but the continuation phase is extended such that total
duration of treatment is 9 months.
Section 3: Pulmonary
tuberculosis associated with medical disease or special settings
Category A: Diabetes mellitus
The recommendation is as
in section 1 category Al but the continuation phase is extended such that
the total duration is 9 months.
Category B: Immunodeficient
patients
Recommendation is same as
for section 1 category Al but total duration should be 9 months.
For re-treatment and drug resistant cases the recommendations are the same
for seronegative patients except that a longer duration of treatment is necessary.
Universal precaution and infection control measures should be strictly enforced,
if drugs are to be given by injection.
Category C: Pregnancy
All the first line drugs can
be used with the exception of streptomycin because of foetal ototoxicity.
The safety of the second line drugs and ofloxacin have not been established
and these drugs should be avoided. The taking of anti-tuberculous drugs is
itself not a contraindication to breast-feeding.
Category D: Children
The regimens are similar
to the adult regimens except that ethambutol should be avoided in children
until they are at least 6 years old and able to report visual changes accurately.
The drug dosages should be based on body weight.
Category E: Liver dysfunction
Transient bilirubin and alanine
transaminase level changes are common and do not indicate true hepatotoxicity.
Drug-induced hepatitis however necessitates the withholding of all drugs
until liver function normalizes. During extensive disease and pending full
recovery of liver function, ofloxacin can be used together with streptomycin
and ethambutol as an interim measure. Experience has shown that optimal dose
for ofloxacin is between 400-600mg once daily. Inclusion of ofloxacin as
a component of a definitive regimen should only be considered when the patient
is intolerant of rifampicin and INH given concomitantly. Optimal duration
of ofloxacin - containing regimens should be at least 1 year.
Category F: Renal impairment
The development of drug induced
renal impairment is an indication for the withdrawal of streptomycin or rifampicin.
If there is pre-existing renal impairment, rifampicin, INH and pyrazinamide
can be given in the usual doses. However in severe renal impairment INH should
be given at 200mg once daily with pyridoxine to avoid peripheral neuropathy.
Streptomycin and ethambutol require the renal route for elimination and
should be used with caution in patients with renal impairment.
REFERENCES
-
Hart
P, DArcy. Chemotherapy of tuberculosis: research during the past 100
years. Br Med J 1946; 2: Part I, 805 - 810; Part II, 849-855.
-
Schatt
A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity
against gram-positive and gram-negative bacteria. Proc Soc Exper Biol Med
1946; 55: 66 - 69.
-
Buttle
GAH, Parish NJ. Treatment of experimental tuberculosis with sulphonamides.
Br Med J 1938; 2: 776.
-
Birkhaug
K. Treatment of experimental 1tuberculosis with sulphonamides. Br Med
J 1939; 2:
54 - 57.
-
Hinshaw
HC. Treatment of experimental tuberculosis with promine. JANA 1941;
117: 1066 - 1068.
-
Feldman
WR, Hinshaw HC, Mann FC. Streptomycin in experimental tuberculosis.
Am Rev Tuberc 1945; 52: 269 298.
-
Youmann
SGP, McCarter JC. Streptomycin in experimental tuberculosis. Am Rev
Tubercle 1945; 52: 432 - 439.
-
British
Medical Research Council - streptomycin treatment of pulmonary tuberculosis:
a medical research council investigation. Br Med J 1948; 2: 769 - 782.
-
Streptomycin
Committee Central Office, Veterans Administration. The effect of streptomycin
upon tuberculosis: preliminary report of a cooperative study of 223 patients
by the army, navy and veterans administration. Am Rev Tubercle 1948; 56:
485 - 507.
-
Tucker
WB. Evaluation of streptomycin regimens in the treatment of tuberculosis:
an account of the study of the veterans administration, army and navy.
July 1946 to April 1949.
-
Bignall
JR. Intermittent dosage in the treatment of pulmonary tuberculosis: a report
of the streptomycin in tuberculosis committee of the medical research council.
Br Med J 1950; 1: 1224 - 1230.
-
Lehman
J. Para-amino salicylic acid in the treatment of pulmonary tuberculosis.
Lancet 1946; 1: 15 - 16.
-
Vallentin
G. PAS in pulmonary tuberculosis. Tubercle 1950; 31: 2-10.
-
British
Medical Research Council. Treatment of pulmonary tuberculosis with para-amino
salicylic acid and streptomycin: preliminary report. Br Med J 1949; 2: 1521.
-
British
Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin
and para-amino salicylic acid: a medical research council investigation.
Br Med J 1950; 2:1073 - 1085.
-
Transactions
of the 9th streptomycin conference on the chemotherapy of tuberculosis.
Veterans Administration. St. Louis, Pulmonary Tuberculosis 1950; 30 - 36.
-
British
Medical Research Council. The treatment of pulmonary tuberculosis with isoniazid:
an interim report. Br Med J 1952; 2: 735 - 746.
-
British
Medical Research Council. Various combinations of isoniazid with streptomycin
or PAS in the treatment of pulmonary tuberculosis. 7th report of the Medical
Research Council. Br Med J 1955; 1: 435 - 445.
-
Crofton
J. Drug treatment of tuberculosis. Standard chemotherapy. Br Med J 1960;
2: 170 - 173.
-
Livings
DG. Transactions of the 17th conference on the chemotherapy of tuberculosis:
results of original course of chemotherapy for pulmonary tuberculosis:
data from cooperative study. General regimens of PAS, INH, streptomycin
daily,
INH streptomycin, PAS daily. Memphis, 1959; 19 - 27.
-
British
Medical Research Council. Long-term chemotherapy of chronic tuberculosis
with cavitation. Tubercle 1962; 43: 201 - 267.
-
Tuberculosis
Chemotherapy Centre, Madras. A concurrent comparison of home and sanatorium
treatment of pulmonary tuberculosis. Bull WHO 1959; 21: 51 - 144.
-
Tuberculosis
Chemotherapy Centre, Madras. A concurrent comparison of twice-weekly
isoniazid plus streptomycin and daily isoniazid plus PAS in domiciliary
treatment.
Lancet 1963; 1: 1078 - 1080.
-
Batten
J. Rifampicin in the treatment of experimental tuberculosis in mice. Sterilization
of tubercle bacilli in the tissues. Tubercle 1970; 51: 95.
-
Grosset
J. The sterilization value of rifampicin and pyrazinamide in experimental
short-course chemotherapy. Tubercle 1978; 59: 287.
-
Dickinson JM,
Mitchison DA. Experimental models to explain the high sterilizing activity
of rifampicin in the treatment of tuberculosis. Am Rev Respir Dis 1981; 12S:
367 - 371.
-
Verbist
L, Gyselen A. Anti-tuberculous activity of rifampicin in vivo and in
vitro and the concentrations attained in human blood. Am Rev Respir Dis
1968; 98:
923 932.
-
Batten
J: Experimental chemotherapy of tuberculosis. Br Med J 1968; 3: 75 - 82.
-
Grumbach F. Experimental in vivo
studies on new anti-tuberculous drugs: capreomycin, ethambutol, and rifampicin.
Tubercle 1969; 50 (Supplement): 12 - 21.
-
Newman
R Rifampicin in the initial treatment of pulmonary tuberculosis. Am Rev Respir
Dis 1971; 103: 461 - 476.
-
Fox
W. The current status of shod-course chemotherapy. Tubercle 1979; 60: 177
- 190.
-
WHO
Global Tuberculosis Control. WHO report. WHO, Geneva 1998; WHOIVB/98-23
7.
-
Chemotherapy
of tuberculosis in Hong Kong: a consensus statement. HKMC 1998; 4:
315 - 319.
Copyright 2004 - Annals of African Medicine
|